Biotech Advances in the Spotlight at BioTrinity 2008

Share Article

BioTrinity, Oxfordshire Bioscience Networks' leading partnering and networking event, will this year focus on the current trends and latest issues affecting the UK's fast growing biotech industry.

BioTrinity, Oxfordshire Bioscience Networks' leading partnering and networking event, will this year focus on the current trends and latest issues affecting the UK's fast growing biotech industry. This year's agenda will feature a number of keynote speakers, currently achieving considerable milestones in today's volatile economic climate. Dr Christian Rohlff, CEO, Oxford Genome Sciences (OGeS) is the most recent speaker to confirm his position on the programme.

Useful information for press:

In the past two years OGeS has positioned itself as an emerging force in the field of novel antibody therapeutics for the treatment of cancer. In December, as part of this strategy, the company announced a partnership with Amgen, one of the world's largest biotechnology companies, which will provide OGeS with access to the US company's XenoMouse technology for antibody generation. Dr. Rohlff will be speaking at the 'Most Promising Emerging Companies Showcase.'

Oxford Genome Sciences is one of twenty five of the most promising emerging drug discovery companies in the South East of England chosen for BioTrinity by an expert panel put together by the Oxfordshire Bioscience Network (OBN).
Other speakers at BioTrinity 2008 include:

Charlie Alexander, Director of Business Development, Shire
Shaun Grady, VP Deal Management, AstraZeneca
Graziano Seghezzi, Partner, Sofinnova Partners
Zina Affas, Principal (Life Sciences), Atlas Venture
David Mott, Investment Director, Oxford Capital Partners
Edwin Moses, Chairman & CEO, Ablynx
Eliot Forster, CEO, Solace Pharma
Charles Potter, CEO, Glide Pharma
Anker Lundemose, President, (OSI) Prosidion
Steven Lee, CEO, Summit plc
Thomas Schall, CEO, Chemocentryx
Robert Miller, CEO, Phynova
Mark Ashton, EVP Business Development, Evotec

Dr. Jon Rees, Director of OBN commented: "We are very pleased to be host to so many prestigious speakers at BioTrinity 2008, specifically Dr. Rohlff. Oxford Genomes Sciences' recent announcement of a deal with Amgen is highly significant in the development of novel antibody therapies and for the future of drug discovery and development. OGeS's involvement in BioTrinity 2008 will enable delegates and contributors to receive the most up-to-date account of developments in this area and will provide them with the opportunity to participate in partnering discussions with key industry players."

Dr Rohlff Commented: "I am very pleased to be speaking at BioTrinity and to have the opportunity to set out how OGeS has transformed itself from a biomarker development company to an emerging force in the field of novel antibody therapeutics for the treatment of cancer. To achieve this goal OGeS has had a very pro-active business development strategy and we now have strategic partnerships with leading antibody companies including Medarex, Amgen and BioSite. These partnerships have allowed us to create a pipeline of novel antibody therapeutics based on our unique OGAP® (Oxford Genome Anatomy Project) platform, the world's largest proprietary human protein database. I look forward to discussing these collaborations and sharing our vision for the future of the industry with the attendees at BioTrinity."

BioTrinity is taking place on the 15th and 16th April Oxford, UK and provides the opportunity to view the latest presentations from top tier companies from the UK's most successful biotech super cluster in Oxford and the South East of England.
More conference details are available online at: BioTrinity

Register now to receive your complimentary press pass:

De Facto Communications

Gemma Ryan
Tel: +44 (0) 20 7861 3838
g.ryan(at)defacto.com

Notes to Editors:

About Oxford Genome Sciences
Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP®, which it has developed into the world's largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics. OGeS' strategy is to use its unique and integrated OGAP® discovery platform in alliances with the world's leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of cancer. Specifically in 2006, OGeS entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP®
Oxford Genome Anatomy Project (OGAP) holds the world's largest proprietary collection of proteins represented by the database. It integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues and representing 60 diseases and contains over one million peptide sequences, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. OGAP oncology contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies. OGAP® is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see OGeS
or contact:

Oxford Genome Sciences
Dr Christian Rohlff, Chief Executive Officer
Tel: +44 (0)1235 861770
christian.rohlff(at)oxfordgenomesciences.com

Bio Trinity 2008, 15-16 April 2008, Oxford, is the country's leading biotech networking event. It will showcase the Southern UK's biotechnology super cluster, which leads the UK in attracting investment. Twenty-five of the most promising drug discovery and development, diagnostics and medical device companies have been selected to be featured in BioTrinity's "Most Promising Emerging Company Showcase" and "Clinical Stage Developments" featuring the region's drug pipeline. There are also: one-to-one partnering meetings, a licensing and spin-out technology showcase, an exhibition and a number of workshops. More conference details are available online at http://www.biotrinity.com

OBN is the South East's leading biotech business network, catalysing the growth and development of the Oxford and the South East biotech and healthcare biotech super-cluster. Launched by Lord Sainsbury in 1999, OBN is a financially self-sustainable network which raises 99% of its operating costs from private sources and operational activity, as well as membership. In the past 8 years, OBN has delivered over 90 meetings, attracting thousands of delegates, most notably its trademark BioTuesday biotech business networking evenings and BioTrinity, its annual partnering conference. More information is available online at http://www.oxfordshirebioscience.net OBN

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Rees
OBN
+44 (0)1865 594642
Email >

Jon Rees
OBN
+44 (0)1865 594642
Email >
Visit website